Medvi vs Ro

Medvi vs Ro. Medvi or Ro for GLP-1 weight loss? We compared pricing, medications, and real reviews to find the better option. MedVi and Ro represent two fundamentally different approaches to GLP-1 weight loss treatment. MedVi is a flat-rate, cash-pay telehealth platform that bundles everything into one monthly price. Ro is a membership-based platform that helps you access brand-name FDA-approved medications, often through insurance. Choosing between them comes down to whether you want simplicity and affordability or brand-name drugs with insurance support. This comparison breaks down every meaningful difference between MedVi and Ro: pricing models, medications, clinical support, insurance, side effects, and which platform makes more sense for different types of patients. MedVi: All-Inclusive GLP-1 at a Flat Rate MedVi is a bundled cash-pay telehealth platform. You pay one flat monthly fee — typically $199–$299 — and that covers everything: the telehealth consultation, compounded GLP-1 medication (semaglutide or tirzepatide), and shipping to your door. No insurance paperwork, no pharmacy runaround, no hidden costs. MedVi has served over 500,000 patients, generated $1.6 billion in first-year revenue, offers 24/7 unlimited clinical support, and carries LegitScript verification. MedVi prescribes compounded semaglutide and tirzepatide — the same active ingredients in Ozempic/Wegovy and Mounjaro/Zepbound — produced by licensed U.S. 503B compounding pharmacies at a fraction of the brand-name price. The medications are not FDA-approved as finished products, but the active compounds are identical. Ro: Insurance-First with Brand-Name Medications Ro is a membership-based telehealth platform that takes the opposite approach. You pay a monthly membership fee (starting at $45 for the first month, then $145/month) that covers access to the clinical platform, provider consultations, and care coordination. The medication itself is a separate cost — either covered by your insurance or paid out of pocket at retail or discounted pricing. Ro prescribes FDA-approved brand-name medications : Wegovy (semaglutide), Zepbound (tirzepatide), and other branded GLP-1 drugs. If your insurance covers GLP-1s, Ro can be cost-effective. But if your insurance doesn't cooperate, Ro's total cost — membership plus medication — can easily exceed $500/month. Pricing Breakdown MedVi's pricing is straightforward: you pay $199–$299 per month, and that's it. Medication, consultation, follow-ups, and shipping are all included. There's no first-month discount that jumps to a higher price — what you see at checkout is what you pay. Ro's pricing is more layered. The membership starts at $45 for the first month, then $145/month ongoing. That membership fee does not include the medication. If your insurance covers Wegovy or Zepbound, you may only pay a co-pay on top of the membership — potentially making Ro cheaper. But if insurance denies coverage, you're looking at the membership fee plus retail medication cost, pushing your total well above $500/month. Insurance: The Deciding Factor If you have strong insurance that covers GLP-1 medications for weight loss, Ro is worth considering. The platform handles prior authorizations, appeals, and pharmacy coordination. For patients with comprehensive coverage, the $145/month membership plus a low co-pay could be the most affordable path to brand-name Wegovy or Zepbound. If you don't have GLP-1 coverage — and most insurance plans still don't — MedVi is the more practical choice. You skip the insurance uncertainty entirely and get a known, fixed monthly cost for the same active compounds. MedVi's cash-pay model eliminates the insurance variable completely. Clinical Support and Provider Access MedVi offers 24/7 unlimited clinical support — you can reach a medical professional at any hour. When you're dealing with nausea at midnight or have questions about adjusting your dose, that around-the-clock availability matters. MedVi has served over 500,000 patients, and that scale means the support infrastructure has been tested and refined. Ro provides clinical support through its app and messaging system, with access to your care team during standard business hours. The platform has been operating since 2017 and has treated millions of patients. Both platforms provide legitimate clinical oversight; the key difference is MedVi's always-on availability. Side Effects and Safety The side effects of GLP-1 medications are determined by the active compound, not the platform prescribing them. Whether you get semaglutide from MedVi (compounded) or Ro (brand-name Wegovy), the most common side effects are the same: nausea, constipation, diarrhea, stomach pain, and decreased appetite. These typically subside during the first 4–8 weeks. Where the platforms differ on safety is medication provenance. Ro prescribes FDA-approved finished products from Novo Nordisk and Eli Lilly. MedVi's compounded medications contain the same active ingredients but are produced by compounding pharmacies under different regulatory oversight. Both are legal and medically valid. Weight Loss Results Published clinical trial data for semaglutide shows average weight loss of 15–17% of body weight over 68 weeks. Tirzepatide showed even stronger results at 20–26%. These outcomes apply regardless of whether you're using brand-name or compounded versions — the active compound does the same thing in your body either way. MedVi patients consistently report 1–2 lbs per week of weight loss when combining medication with dietary changes. Ro publishes similar outcome expectations. The platform choice should be based on cost, convenience, and clinical support — not on promises of superior weight loss. User Experience and Onboarding MedVi's onboarding is designed for speed. You complete a health questionnaire, get matched with a licensed clinician, and medication ships within days. The entire process typically takes under a week. No insurance step, no pharmacy coordination, no waiting for prior authorization. Ro's onboarding includes an insurance verification step that can add days or weeks, depending on your insurer. If insurance is denied, you'll need to decide whether to pay Ro's cash price or explore other options. The upside is that if insurance covers it, you'll save substantially. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.